Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating HIV
First Claim
Patent Images
1. An isolated, irreversibly inactivated peptide characterized by the amino acid sequence of SEQ ID:
- NO 1.
1 Assignment
0 Petitions
Accused Products
Abstract
The inventions provide an isolated antiviral peptide characterized by the amino acid sequence GDEPLENYLDTEYF (SEQ ID:NO 1) and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. It has postulated anti-retroviral activity in vivo, particularly anti-HIV-1 activity. The inventions further provide pharmaceutical compositions comprising this peptide and methods for preventing, treating, and diagnosing HIV-1 infections and HIV-1 related conditions such as AIDS and ARC with these compositions.
11 Citations
27 Claims
- 1. An isolated, irreversibly inactivated peptide characterized by the amino acid sequence of SEQ ID:
-
12. A 45 kd antiviral pepsinogen fragment having a binding affinity for an HIV-1 envelope protein or a CD4+cell or both.
-
27. A method for producing an inactivated pepsin fraction comprising:
-
preparing a solution of pure pepsin at a first near-neutral pH;
reducing the pH of the solution to an acid pH;
precipitating protein from the solution with a precipitant;
neutralizing and suspending the precipitated protein at a second near-neutral pH; and
purifying an inactivated pepsin fraction to obtain an inactivated pepsinogen fragment (IPF) comprising a 45 kD peptide with an amino acid sequence homologous to pepsin.
-
Specification